IGC Pharma(IGC)

Focus: IGC Pharma is a public-stage pharmaceutical company focused on cannabinoid-based therapies for neurology, specifically Alzheimer's disease. The company operates at minimal scale with ~$1M in annual revenue and is headquartered in Potomac, MD.

Neurology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About IGC Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow IGC Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$1M

FY2025

Pipeline & Clinical Trials

Edutainment Content: Norms Campaign

Intimate Partner Violence (IPV)

N/A

Exposure

COVID-19

N/A

IGC AD1

Help build intelligence for IGC Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering cannabinoid therapeutics in Alzheimer's, a high-unmet-need neurology indication with significant commercial potential
Public company status provides liquidity and potential equity upside for early-stage employees
Exceptionally high R&D intensity (281%) signals commitment to drug development despite pre-commercial stage

Watch Out For

Severe cash constraints ($1M cash, $13M net loss in FY2025) create sustainability risk and potential runway concerns
Only 2 active clinical trials (Phase 1 and Phase 2) with no Phase 3 programs suggest early-stage risk and multi-year path to approval
Zero open job postings indicate no active hiring and possible organizational contraction

Generated by Claude from IGC Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Clinical Trials (1)

NCT04749563Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Phase 1

IGC-AD1-Active

Alzheimer Disease

PHASE_2

Clinical Trials (1)

NCT05543681Clinical Trial on Agitation in Alzheimer's Dementia

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Neurology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$1M48%

R&D Spend

$4M(281%)9%

Net Income

-$13M